4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide(CAS: 170105-16-5)

4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide (CAS: 170105-16-5) must comply with the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), REACH regulations for European Union, and FDA/EPA requirements for usage and disposal in the USA and EU. Specific handling, storage, and transportation guidelines are outlined in these frameworks to ensure safety and environmental protection.

Various alternatives can be considered in the synthesis of 4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide (CAS: 170105-16-5), including isomers and analogs like 4-(2-Ethyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide. Common substitute reagents include substituted imidazoles and phenyl derivatives, which can provide similar functionalities with varying chemical properties and reactivity.

The market for 4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide (CAS: 170105-16-5) is driven by its applications in pharmaceuticals, particularly as an intermediate in drug synthesis. Research trends focus on its potential in anti-inflammatory and antiviral drug development. Market demand is expected to grow with advancements in biotechnology and medicinal chemistry.

Waste containing 4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide (CAS: 170105-16-5) should be collected in a sealed, appropriately labeled container. Waste disposal should be handled by professional waste management companies that comply with local environmental regulations. Incineration is a common method, but precautions must be taken to minimize environmental impact and ensure compliance with regulatory standards.